Top News and Analysis for R&D and Executive Leaders

 

Week of 10.1.08

tbar.gif


Neil W Gibson of OSI Pharmaceuticals

Jeffrey Settleman Harvard Medical School and MGH Cancer Center

David Bailey of Chemoventures

N Claude Cohen of Synergix

-View All Webcasts

 

 

 
     

 

 

Personalized Medicine

Johns Hopkins Team Identifies Genetic Changes in Breast and Colon Cancers

September 7, 2006--A team of researchers at Johns Hopkins University sequenced the protein-coding regions of some 13,000 genes within each of 11 breast tumors and 11 colon tumors. They identified nearly 200 mutated genes, most of which were not previously known to play a role in cancer. Observed changes were not duplicated from one tumor type to the other. Their work is reported in the September 7 online issue of Science (subscription required to read full text of article). Read the statement from the National Institutes of Health.

 

 

FEATURE:

Prolong Pharmaceuticals – PEGged For Success?
By Alissa Poh

TOct. 1, 2008 | In Britain, people often use the phrase “pegging away” to describe working hard at something.

Across the pond, in New Jersey, the folks at Prolong Pharmaceuticals are also pegging away, attaching polyethylene glycol (PEG) to a variety of protein-based drugs. Or, to use the proper term, “pegylating” these drugs to improve pharmacokinetics, extend circulation time and decrease toxicity, all of which make for enhanced therapeutic effects. 

Read more.

 


 


PharmaWeek
is subject to the terms and conditions of use
Please read the important legal notices and disclaimers contained in these terms and
conditions of use.


Copyright 2005  Cambridge Healthtech Institute  |  250 First Avenue  |   Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425